Metformin use and pancreatic ductal adenocarcinoma outcomes: a narrative review
ANZ Journal of Surgery · 2025
DOI: 10.1111/ans.19405 ↗At a glance
Übersichtsarbeit in ANZ Journal of Surgery, 2025. Written by Dooyeon Lee and 3 co-authors. Institution: Department of Surgery, Western Health, St. Albans, Victoria, Australia. Major MEDLINE topics: Metformin, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Hypoglycemic Agents. Cited 3 times so far (Crossref); 40 references.
Abstract (original language)
Background
Metformin is a diabetes medication with anti‐mitotic properties. A narrative review was performed to investigate people using metformin and the risk of developing pancreatic ductal adenocarcinoma (PDAC) as well as survival outcomes in established PDAC.
Methods
Relevant studies on metformin use and PDAC were retrieved from PubMed including observational studies on metformin and the risk of developing PDAC and survival outcomes in PDAC, and randomized controlled trials of metformin as a treatment in PDAC.
Results
Of the 367 studies searched, 26 studies fulfilled the criteria for this review. Metformin was not consistently associated with a reduced risk of developing PDAC. However, metformin use, especially higher cumulative doses, in some studies was associated with longer survival in patients with established PDAC, especially in the subgroup with resectable PDAC. Metformin use was not associated with longer survival in more advanced (non‐resectable metastatic) PDAC.
Conclusion
Metformin was not consistently associated with a reduced risk of developing PDAC. Metformin may be associated with overall survival benefits in patients with PDAC including the resectable PDAC subgroup but not in the metastatic PDAC subgroup. The evidence to date does not support the routine use of metformin as an adjuvant therapy for advanced PDAC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Surgery, Western Health, St. Albans, Victoria, Australia.
- Victorian Oncology Care, St John of God Specialist Centre, Berwick, Victoria, Australia.
- Department of Diabetes & Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
- Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.
- Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.
- Clinical Institute General Surgery and Gastroenterology, Epworth Healthcare, Richmond, Victoria, Australia.
ORCID profiles: Dooyeon Lee
Cite
APA
Lee, D., Liew, M. S., Fourlanos, S., & Choi, J. (2025). Metformin use and pancreatic ductal adenocarcinoma outcomes: a narrative review. ANZ Journal of Surgery. https://doi.org/10.1111/ans.19405
Vancouver
Lee D, Liew MS, Fourlanos S, Choi J. Metformin use and pancreatic ductal adenocarcinoma outcomes: a narrative review. ANZ Journal of Surgery. 2025. doi:10.1111/ans.19405
BibTeX
@article{Lee2025,
author = {Lee, Dooyeon and Liew, Mun Sem and Fourlanos, Spiros and Choi, Julian},
title = {Metformin use and pancreatic ductal adenocarcinoma outcomes: a narrative review},
journal = {ANZ Journal of Surgery},
year = {2025},
doi = {10.1111/ans.19405}
}
EUVIMED